Free Trial
OTCMKTS:CZMWY

Carl Zeiss Meditec (CZMWY) Stock Price, News & Analysis

$99.09
-3.18 (-3.11%)
(As of 05/23/2024 05:38 PM ET)
Today's Range
$99.03
$100.65
50-Day Range
$99.09
$131.01
52-Week Range
$77.44
$134.60
Volume
1,611 shs
Average Volume
988 shs
Market Capitalization
N/A
P/E Ratio
107.71
Dividend Yield
0.30%
Price Target
N/A
CZMWY stock logo

About Carl Zeiss Meditec Stock (OTCMKTS:CZMWY)

Carl Zeiss Meditec AG operates as a medical technology company in Germany, rest of Europe, North America, and Asia. It operates in two segments, Ophthalmology and Microsurgery. The Ophthalmology segment offers products and solutions for the diagnosis and treatment of chronic eye diseases, such as ametropia (refraction), cataracts, glaucoma, and renital disorders. This segment also provides devices for general ophthalmological examination and care, including slit lamps, refractometers, tonometers, optical coherence tomography devices, and fundus cameras; and devices for functional diagnostics (perimeters), as well as digital products for storage, evaluation, and sharing of clinical data. In addition, this segment offers surgical ophthalmology products comprising surgical microscopes, biometers, phacoemulsification, and vitrectomy devices; intraocular lenses for cataract patients; and systems and consumables for laser eye surgery. The Microsurgery segment provides products and solutions for invasive surgical treatments; and solutions in the area of ear, nose and throat, plastic and reconstructive, neuro, dental, and spinal surgeries. It serves physicians in various fields and hospitals. The company was founded in 1846 and is headquartered in Jena, Germany. Carl Zeiss Meditec AG is a subsidiary of Carl Zeiss AG.

CZMWY Stock Price History

CZMWY Stock News Headlines

Carl Zeiss Meditec (OTCMKTS:CZMWY) Trading Down 3.1%
Carl Zeiss Meditec AG (CZMWY)
EQS-Adhoc: Carl Zeiss Meditec AG announces agreement to acquire D.O.R.C.
Zeiss Meditec buys Dutch firm for nearly 1 bln euros
Carl Zeiss Meditec Ag (ETR: AFX)
CZMWF Carl Zeiss Meditec AG
Carl Zeiss Meditec Ag (OTC: CZMWF)
See More Headlines
Receive CZMWY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Carl Zeiss Meditec and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Ex-Dividend for 4/9 Dividend
3/21/2024
Ex-Dividend for 4/10 Dividend
3/22/2024
Dividend Payable
4/09/2024
Dividend Payable
4/10/2024
Today
5/24/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Medical Instruments & Supplies
Sub-Industry
N/A
Current Symbol
OTCMKTS:CZMWY
CIK
N/A
Fax
N/A
Employees
4,823
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
N/A
Beginners Guide To Retirement Stocks Cover

Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Key Executives

  • Dr. Markus Weber
    CEO & Chairman of Management Board
  • Mr. Justus Felix Wehmer (Age 59)
    CFO & Member of the Management Board
    Comp: $650.23k
  • Dr. Christian Munster (Age 53)
    Head of Global Regulatory & Clinical Affairs, CoCe Site Jena & Emp. Rep. Member of Supervisory Board
  • Stefanie Spanagel
    Chief Operating Officer
  • Mr. Sebastian Frericks
    Director of Investor Relations
  • Eva-Maria Heine
    Chief Human Resources Officer
  • Mr. Steven C. Schallhorn M.D.
    Chief Medical Officer for Global Ophthalmic Devices
  • Mr. Andrew Chang
    Head of Sales for Ophthalmic Devices & President of Carl Zeiss Meditec, Inc.
  • Dr. Euan S. Thomson Ph.D. (Age 61)
    President of Ophthalmic Devices and Head of the Ophthalmic Devices Strategic & Digital Business Unit
  • Mr. Magnus Reibenspiess
    Head of the Microsurgery Strategic Business Unit - ZEISS Medical Technology

CZMWY Stock Analysis - Frequently Asked Questions

Should I buy or sell Carl Zeiss Meditec stock right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Carl Zeiss Meditec in the last year. There are currently 2 hold ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" CZMWY shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CZMWY, but not buy additional shares or sell existing shares.
View CZMWY analyst ratings
or view top-rated stocks.

How have CZMWY shares performed in 2024?

Carl Zeiss Meditec's stock was trading at $109.1439 at the beginning of 2024. Since then, CZMWY shares have decreased by 9.2% and is now trading at $99.09.
View the best growth stocks for 2024 here
.

Are investors shorting Carl Zeiss Meditec?

Carl Zeiss Meditec saw a decrease in short interest in April. As of April 15th, there was short interest totaling 100 shares, a decrease of 75.0% from the March 31st total of 400 shares. Based on an average daily volume of 1,600 shares, the short-interest ratio is presently 0.1 days.
View Carl Zeiss Meditec's Short Interest
.

How often does Carl Zeiss Meditec pay dividends? What is the dividend yield for Carl Zeiss Meditec?

Carl Zeiss Meditec announced a dividend on Tuesday, February 27th. Investors of record on Monday, March 25th will be given a dividend of $0.8282 per share on Wednesday, April 10th. The ex-dividend date of this dividend is Friday, March 22nd.
Read our dividend analysis for CZMWY
.

Is Carl Zeiss Meditec a good dividend stock?

Carl Zeiss Meditec (OTCMKTS:CZMWY) pays an annual dividend of $0.30 per share and currently has a dividend yield of 1.36%. The dividend payout ratio is 32.64%. This payout ratio is at a healthy, sustainable level, below 75%.
Read our dividend analysis for CZMWY.

How do I buy shares of Carl Zeiss Meditec?

Shares of CZMWY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (OTCMKTS:CZMWY) was last updated on 5/24/2024 by MarketBeat.com Staff

From Our Partners